Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 1:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 565 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Cequa Clear all

Conditions: Alopecia Areata
Interventions: CycloSPORINE Injectable Product, Saline Solution; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Neural Tube Defects, Anemia, Leukemia, Myeloid, Bone Marrow Transplant Failure, Myelodysplastic Syndromes (MDS), Myeloproliferative Disorders
Interventions: CIK cells, Cyclosporine, Mycophenolate Mofetil, Thymoglobulin, Total Lymphoid Irradiation (TLI); Drug · Radiation
Lead sponsor: Everett Meyer; Other
Eligibility: 50 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Stanford, California

Conditions: Leukemia, Lymphoma, Hodgkin's Disease, Hematologic Neoplasms, Multiple Myeloma, Carcinoma, Renal Cell
Interventions: Pentostatin, Alemtuzumab, Allogeneic hematopoietic stem cell transplantation; Drug · Biological · Procedure
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 75 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 2
States / cities: Tucson, Arizona

Conditions: Refractory Non Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma
Interventions: rituximab, ibritumomab tiuxetan, anti-thymocyte globulin, total nodal irradiation, peripheral blood stem cell transplantation, allogeneic hematopoietic stem cell transplantation, cyclosporine, mycophenolate mofetil; Biological · Radiation · Procedure + 1 more
Lead sponsor: Joseph Tuscano; Other
Eligibility: 19 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Dry Eye Syndrome
Interventions: No Intervention; Other
Lead sponsor: Hazleton Eye Specialists; Other
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Hazleton, Pennsylvania

Conditions: Ulcerative Colitis Acute
Interventions: Cyclosporine Injection (IV), Cyclosporine Oral Product, Upadacitinib Extended Release Oral Tablet, Intravenous Methylprednisolone, Prednisone Oral Product; Drug
Lead sponsor: Berinstein, Jeffrey; Other
Eligibility: 18 Years to 75 Years
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Leukemia, Myelodysplastic Syndrome, Non-Hodgkins Lymphoma, Chronic Myelogenous Leukemia, Hodgkins Lymphoma
Interventions: fludarabine, cyclophosphamide, thiotepa, radiation therapy, unrelated donor umbilical cord blood graft; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: filgrastim, graft-versus-tumor induction therapy, rituximab, therapeutic allogeneic lymphocytes, cyclophosphamide, cyclosporine, cytarabine, doxorubicin hydrochloride, etoposide, fludarabine phosphate, prednisone, vincristine sulfate, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: SARS (Disease)
Interventions: Cyclosporine, Standard of Care Treatment; Drug · Other
Lead sponsor: Bryan Burt, MD; Other
Eligibility: 18 Years to 90 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Keratoconjunctivitis Sicca, Sjogren's Syndrome
Interventions: Cyclosporin A; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Dry Eye
Interventions: Cyclosporine, Artificial tear; Drug
Lead sponsor: Vishal Jhanji; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Acute, Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse
Interventions: Hematopoietic Umbilical Cord Blood Stem Cell Transplantation, GVHD prophylaxis; Biological
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 1 Year to 70 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 16
States / cities: Duarte, California • Gainesville, Florida • Tampa, Florida + 12 more

Conditions: Kidney Transplantation, Graft Rejection
Interventions: Everolimus, Mycophenolic Acid (MPA), Cyclosporine A (CsA), Basiliximab, Corticosteroids; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 833 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: HIV Infections
Interventions: Cyclosporine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 12
States / cities: San Francisco, California • Denver, Colorado • Chicago, Illinois + 7 more

Conditions: Cytomegalovirus Infections, Transplant-Related Disorder
Interventions: Letermovir 480 MG [Prevymis]; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hematopoietic Stem Cell Transplant, GVHD
Interventions: 70% Ethanol; Other
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 3 Months to 30 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Heart Transplantation
Interventions: Daclizumab, Methylprednisolone, Mycophenolate mofetil, Placebo, cyclosporine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 13 Years and older
Enrollment: 434 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 25
States / cities: Birmingham, Alabama • Los Angeles, California • Tampa, Florida + 19 more

Conditions: Hemophagocytic Lymphohistiocytosis, X-Linked Lymphoproliferative Disorders, Chediak-Higashi Syndrome, Griscelli Syndrome, Immunologic Deficiency Syndromes, Langerhans-Cell Histiocytosis
Interventions: Stem Cell Transplant, Fludarabine, Melphalan, Anti-thymocyte globulin (ATG), Campath 1H, Cyclosporin A, Mycophenolate mofetil, Intravenous immunoglobulin (IVIG); Procedure · Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 35 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2014
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Type 1 Diabetes Mellitus, Hypoglycemia
Interventions: Allogeneic Islets of Langerhans, Everolimus, anti-thymocyte globulin, Cyclosporine; Biological · Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Aplastic Anemia
Interventions: anti-thymocyte globulin, cyclophosphamide, cyclosporine, mesna, methotrexate, methylprednisolone; Drug
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 0 Years to 55 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1995
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: AML, ALL, Undifferentiated Leukemia, Biphenotypic Leukemia, Refractory Anemia, Refractory Anemia With Ringed Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Ref. Cytopenia w Multilineage Dysplasia & Ringed Sideroblasts, Refractory Anemia With Excess Blasts-1 (5-10% Blasts), Refractory Anemia With Excess Blasts-2 (10-20% Blasts), Myelodysplastic Syndrome, Unclassified, MDS Associated With Isolated Del (5q)
Interventions: Abatacept; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 12 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: anti-thymocyte globulin, busulfan, cyclosporine, melphalan, methotrexate, methylprednisolone, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, umbilical cord blood transplantation; Biological · Drug · Procedure
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: Up to 30 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Autoimmune Diseases
Interventions: Efalizumab; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Acute Lymphoblastic Leukemias, Acute Myelocytic Leukemia, Chronic Myeloid Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndrome, Hemoglobinuria, Paroxysmal, Non-Hodgkin Lymphoma
Interventions: Allogeneic Stem Cell Transplantation, Chemotherapy and antibodies; Procedure · Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 2 Years to 21 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 1
States / cities: Memphis, Tennessee

Search by objective public record fields.

Intralesional Cyclosporine for Alopecia Areata

Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders

Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation

Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

A Retrospective Analysis of Restasis® Benefits in Dry Eye Contact Lens Patients

Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis

Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.

T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies

Cyclosporine For The Treatment Of COVID-19(+)

Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops

Tear Film Markers in Dry Eye Syndrome

Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604)

Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients

A Study to Test the Effect of Cyclosporine on the Immune System of Patients With Early HIV Disease

Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients

70% Ethanol for Decontamination of CVL Exposed to Calcineurine Inhibitors Version 1.0, 1/9/2014

A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation

Stem Cell Transplant for Immunologic or Histiocytic Disorders

Anti-Thymocyte Globulin, Cyclosporine, and RAD in Islet Transplantation

Phase II Study of Bone Marrow Transplantation Using Related Donors in Patients With Aplastic Anemia

Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT

Donor Stem Cell Transplant in Treating Young Patients With Relapsed or Refractory Solid Tumors

Pilot Trial to Assess Effect of CNI Conversion of Efalizumab on T Reg Cells

Stem Cell Transplantation for Patients With Hematologic Malignancies